More from Front Line Genomics
Cofactor Genomics, the developer of advanced RNA analysis tools, has announced that it has entered into an agreement with the National Cancer Institute, to demonstrate the clinical utility of its immune-profiling assay, Cofactor Paragon.
A new promising drug that could prove an effective treatment for breast cancer patients who have proved unresponsive to hormone therapy, has entered human trials.
A new study by Cancer Research UK has found that more than 135,500 cases of cancer every year in the UK could be prevented through lifestyle changes.
Researchers have developed a test that provides a safe and minimally invasive method for earlier diagnosis of ovarian and endometrial cancers.